William H Polonsky1, Lawrence Fisher2, Danielle Hessler2, Steven V Edelman3. 1. 1 Department of Psychiatry, University of California , San Diego, and Behavioral Diabetes Institute, San Diego, California. 2. 2 Department of Family and Community Medicine, University of California , San Francisco, San Francisco, California. 3. 3 Division of Endocrinology and Metabolism, University of California , San Diego, and Veterans Affairs Medical Center, San Diego, California.
Abstract
BACKGROUND: While research designed to understand the concerns about hypoglycemia among patients with diabetes has been primarily focused on the investigation of fear and anxiety, recent evidence suggests a potentially important and conceptually distinct element-hypoglycemic confidence. To investigate this dimension, we developed the Hypoglycemic Confidence Scale (HCS); herein, we describe the construction and validation of the HCS and examine how key patient factors are associated with hypoglycemic confidence. METHODS: Items were developed from interviews with six type 1 diabetes (T1D) adults, six insulin-using type 2 diabetes (T2D) adults, and seven diabetes healthcare professionals, resulting in nine self-report items. Separate exploratory factor analyses (EFAs) were conducted with T1D adults (N = 326), with T2D adults using both basal and prandial insulins (T2D-BP, N = 145) and with T2D adults using only basal insulin (T2D-BO, N = 82). Construct validity for the HCS was established with overall well-being (World Health Organization-5), diabetes distress (Diabetes Distress Scale), global anxiety (Generalized Anxiety Disorder), hypoglycemic fear (Hypoglycemic Fear Survey-II), and glycemic control (self-reported A1C). Hierarchical regression analyses examined the unique contribution of HCS scores, independent of hypoglycemic fear, on key psychosocial constructs and A1C. RESULTS: EFAs of the nine HCS items yielded a single factor solution for each of the three subject samples, accounting for 50.8%, 65.1%, and 73.7% of the variance for the T1D, T2D-BP, and T2D-BO groups, respectively. Construct validity was established by significant correlations with criterion variables. The HCS was associated with well-being and diabetes distress in the T1D (in both cases, P < 0.001) and T2D-BP groups (in both cases, P < .05) and for self-reported A1C in the T2D-BP group (P < .05) independent of hypoglycemic fear. CONCLUSIONS: Hypoglycemic confidence is a unique dimension of patient experience, different from hypoglycemic fear, and is deserving of further study. The HCS is a reliable valid measure of hypoglycemic confidence for adults with T1D and insulin-using T2D.
BACKGROUND: While research designed to understand the concerns about hypoglycemia among patients with diabetes has been primarily focused on the investigation of fear and anxiety, recent evidence suggests a potentially important and conceptually distinct element-hypoglycemic confidence. To investigate this dimension, we developed the Hypoglycemic Confidence Scale (HCS); herein, we describe the construction and validation of the HCS and examine how key patient factors are associated with hypoglycemic confidence. METHODS: Items were developed from interviews with six type 1 diabetes (T1D) adults, six insulin-using type 2 diabetes (T2D) adults, and seven diabetes healthcare professionals, resulting in nine self-report items. Separate exploratory factor analyses (EFAs) were conducted with T1D adults (N = 326), with T2D adults using both basal and prandial insulins (T2D-BP, N = 145) and with T2D adults using only basal insulin (T2D-BO, N = 82). Construct validity for the HCS was established with overall well-being (World Health Organization-5), diabetes distress (Diabetes Distress Scale), global anxiety (Generalized Anxiety Disorder), hypoglycemic fear (Hypoglycemic Fear Survey-II), and glycemic control (self-reported A1C). Hierarchical regression analyses examined the unique contribution of HCS scores, independent of hypoglycemic fear, on key psychosocial constructs and A1C. RESULTS:EFAs of the nine HCS items yielded a single factor solution for each of the three subject samples, accounting for 50.8%, 65.1%, and 73.7% of the variance for the T1D, T2D-BP, and T2D-BO groups, respectively. Construct validity was established by significant correlations with criterion variables. The HCS was associated with well-being and diabetes distress in the T1D (in both cases, P < 0.001) and T2D-BP groups (in both cases, P < .05) and for self-reported A1C in the T2D-BP group (P < .05) independent of hypoglycemic fear. CONCLUSIONS: Hypoglycemic confidence is a unique dimension of patient experience, different from hypoglycemic fear, and is deserving of further study. The HCS is a reliable valid measure of hypoglycemic confidence for adults with T1D and insulin-using T2D.
Entities:
Keywords:
Confidence; Hypoglycemia; Type 1 diabetes; Type 2 diabetes
Authors: Cari Berget; Kimberly A Driscoll; Ann Lagges; Samantha Lange; Linda A DiMeglio; Tamara S Hannon; Stephanie E Woerner; Esti Iturralde; Regan C Barley; Sarah Hanes; Korey K Hood; Bruce B Buckingham Journal: Contemp Clin Trials Date: 2019-05-23 Impact factor: 2.226
Authors: Gregory P Forlenza; Laurel H Messer; Cari Berget; R Paul Wadwa; Kimberly A Driscoll Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: Lori M Laffel; Lauren G Kanapka; Roy W Beck; Katherine Bergamo; Mark A Clements; Amy Criego; Daniel J DeSalvo; Robin Goland; Korey Hood; David Liljenquist; Laurel H Messer; Roshanak Monzavi; Thomas J Mouse; Priya Prahalad; Jennifer Sherr; Jill H Simmons; R Paul Wadwa; Ruth S Weinstock; Steven M Willi; Kellee M Miller Journal: JAMA Date: 2020-06-16 Impact factor: 56.272
Authors: Heather L Stuckey; Urvi Desai; Sarah B King; Lyuba Popadic; William Levinson; Noam Y Kirson; Emily R Hankosky; Beth Mitchell Journal: Diabet Med Date: 2021-12-15 Impact factor: 4.213
Authors: Yogish C Kudva; Lori M Laffel; Sue A Brown; Dan Raghinaru; Jordan E Pinsker; Laya Ekhlaspour; Carol J Levy; Laurel H Messer; Boris P Kovatchev; John W Lum; Roy W Beck; Linda Gonder-Frederick Journal: Diabetes Technol Ther Date: 2021-10 Impact factor: 7.337
Authors: Arndís F Ólafsdóttir; William Polonsky; Jan Bolinder; Irl B Hirsch; Sofia Dahlqvist; Hans Wedel; Thomas Nyström; Magnus Wijkman; Erik Schwarcz; Jarl Hellman; Tim Heise; Marcus Lind Journal: Diabetes Technol Ther Date: 2018-04-02 Impact factor: 6.118
Authors: Korey K Hood; Lori M Laffel; Thomas Danne; Revital Nimri; Stuart A Weinzimer; Judy Sibayan; Ryan J Bailey; Desmond Schatz; Natasa Bratina; Rachel Bello; Alina Punel; Peter Calhoun; Roy W Beck; Richard M Bergenstal; Moshe Phillip Journal: Diabetes Technol Ther Date: 2021-10-26 Impact factor: 6.118